1. Home
  2. INAB vs BNGO Comparison

INAB vs BNGO Comparison

Compare INAB & BNGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$1.44

Market Cap

13.7M

Sector

Health Care

ML Signal

HOLD

Logo Bionano Genomics Inc.

BNGO

Bionano Genomics Inc.

HOLD

Current Price

$1.17

Market Cap

12.9M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
INAB
BNGO
Founded
2016
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
13.7M
12.9M
IPO Year
2020
2018

Fundamental Metrics

Financial Performance
Metric
INAB
BNGO
Price
$1.44
$1.17
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$6.00
$7.00
AVG Volume (30 Days)
40.1K
130.5K
Earning Date
05-11-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
94.50
EPS
N/A
N/A
Revenue
N/A
$12,000,735.00
Revenue This Year
N/A
$14.99
Revenue Next Year
N/A
$34.73
P/E Ratio
N/A
N/A
Revenue Growth
N/A
26.26
52 Week Low
$1.17
$1.06
52 Week High
$2.73
$5.50

Technical Indicators

Market Signals
Indicator
INAB
BNGO
Relative Strength Index (RSI) 46.12 49.38
Support Level $1.32 $1.13
Resistance Level $1.53 $1.19
Average True Range (ATR) 0.08 0.04
MACD 0.01 0.01
Stochastic Oscillator 60.31 50.00

Price Performance

Historical Comparison
INAB
BNGO

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

About BNGO Bionano Genomics Inc.

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.

Share on Social Networks: